Categories
Prostate cancer

Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis

  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. CA Cancer J Clin. 2022;72:7–33.

    Article 
    PubMed 

    Google Scholar
     

  • Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–62.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA. 1997;94:8099–103.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Graff JN, Puri S, Bifulco CB, Fox BA, Beer TM. Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer. Cancer Immunol Res. 2014;2:399–403.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35:40–47.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700–12.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wattenberg MM, Fong L, Madan RA, Gulley JL. Immunotherapy in genitourinary malignancies. Curr Opin Urol. 2016;26:501–7.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kalina JL, Neilson DS, Comber AP, Rauw JM, Alexander AS, Vergidis J, et al. Immune modulation by androgen deprivation and radiation therapy: implications for prostate cancer immunotherapy. Cancers. 2017;9:13.

    Article 
    PubMed Central 

    Google Scholar
     

  • Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–22.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Karzai F, Madan RA, Owens H, Hankin A, Couvillon A, Houston ND, et al. A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D.; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2017;35:162.

    Article 

    Google Scholar
     

  • Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016;7:52810–7.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, et al. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2022;18:1185–98.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Koinis F, Xagara A, Chantzara E, Leontopoulou V, Aidarinis C, Kotsakis A. Myeloid-derived suppressor cells in prostate cancer: present knowledge and future perspectives. Cells. 2021;11:20.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Garcia AJ, Ruscetti M, Arenzana TL, Tran LM, Bianci-Frias D, Sybert E, et al. Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol. 2014;34:2017–28.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018;559:363–9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Canesin G, Evans-Axelsson S, Hellsten R, Sterner O, Krzyzanowska A, Andersson T, et al. The STAT3 inhibitor galiellalactone effectively reduces tumor growth and metastatic spread in an orthotopic xenograft mouse model of prostate cancer. Eur Urol. 2016;69:400–4.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hellsten R, Lilljebjörn L, Johansson M, Leandersson K, Bjartell A. The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors. Prostate. 2019;79:1611–21.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Won H, Moreira D, Gao C, Duttagupta P, Zhao X, Manuel E, et al. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. J Leukoc Biol. 2017;102:423–36.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Consiglio CR, Udartseva O, Ramsey KD, Bush C, Gollnick SO. Enzalutamide, an androgen receptor antagonist, enhances myeloid cell-mediated immune suppression and tumor progression. Cancer Immunol Res. 2020;8:1215–27.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lerman I, Garcia-Hernandez ML, Rangel-Moreno J, Chiriboga L, Pan C, Nastiuk KL, et al. Infiltrating myeloid cells exert protumorigenic actions via neutrophil elastase. Mol Cancer Res. 2017;15:1138–52.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Matchar DB. Introduction to the methods guide for medical test reviews. J Gen Intern Med. 2012;27:S4–10.

    Article 
    PubMed 

    Google Scholar
     

  • Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in metaanalysis. Biometrics. 2000;56:455–63.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Chi N, Tan Z, Ma K, Bao L, Yun Z. Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer. Int J Clin Exp Med. 2014;7:3181–92.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Idorn M, Køllgaard T, Kongsted P, Sengeløv L, Straten PT. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother. 2014;63:1177–87.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, et al. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer. 2014;2:31.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Koga N, Moriya F, Waki K, Yamada A, Itoh K, Noguchi M. Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine. Cancer Sci. 2017;108:2326–32.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer. 2018;6:141.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Brusa D, Simone M, Gontero P, Spadi R, Racca P, Micari J, et al. Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: profile comparison. Int J Urol. 2013;20:971–8.

    CAS 
    PubMed 

    Google Scholar
     

  • Wang J, McGuire TR, Britton HC, Schwarz JK, Loberiza FR Jr., Meza JL, et al. Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer. Clin Exp Metastasis. 2015;32:111–24.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Vuk-Pavlović S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, et al. Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate. 2010;70:443–55.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Noguchi M, Moriya F, Koga N, Matsueda S, Sasada T, Yamada A, et al. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. Cancer Immunol Immunother. 2016;65:151–60.

    Article 
    CAS 
    PubMed 

    Google Scholar